Searched for
WOCKHARDT REVENUE
Biosimilars and innovation will drive Indian pharma's next growth phase: Vishal ManchandaIndia's pharmaceutical sector is pivoting beyond generics, with companies aggressively pursuing growth in biosimilars, nutraceuticals, and ...- Sweet pills: How pharma stocks delivered bumper returns to Indian investors, defying 2026 whiplashIndian pharma stocks are outperforming the market, offering strong returns to investors. This resilience is driven by robust domestic deman...
- Pharma in her DNA, Wockhardt scion ready for deep dive in the USZahabiya Khorakiwala is leading Wockhardt's US business and the launch of its new antibiotic, Zaynich. This drug targets resistant bacteria...
- Wockhardt shares pause massive 36% rally in 5 sessions; slip 7%. What’s behind the selloff?Wockhardt shares dropped after a recent surge, as investors took profits. This followed the US FDA approval of ZAYNICH, an antibiotic for u...
- Zaynich's blockbuster potential lifts Wockhardt's long-term outlookWockhardt's novel antibiotic, Zaynich, has received USFDA approval after a 12-year effort, sparking hopes for a turnaround after years of n...
- Aegis Logistics shares rally 4% as Q4 profit rises 45% YoY; Board recommends dividendAegis Logistics shares rose sharply after the company reported a 45% year-on-year rise in Q4 FY26 consolidated net profit to Rs 413 crore, ...
- Laurus Labs adds Rs 40,150 crore to investors' wealth in a year with 120% rally. Buy, hold or book profits?Laurus Labs has significantly boosted investor wealth, adding over Rs 40,000 crore in a year with a 120% stock rally. Driven by business im...
- Ahead of Market: 10 things that will decide stock market action on ThursdayDomestic equities surged as crude oil slipped below $100 and US-India trade optimism boosted sentiment. Nifty and Sensex gained over 1%, le...
- Small & midcaps rally! Wockhardt, Coforge, other stocks surge up to 14%. Do you own any?Smallcap and midcap stocks surged on Wednesday, outperforming broader market indices with gains of around 1% each. This rally was fueled by...
- Smallcap winners! Wockhardt, Tata Tech, CAMS, other stocks rally up to 11% despite overall market weaknessSmallcap stocks outperformed on Tuesday despite weak broader markets, with Wockhardt, Tata Tech and CAMS gaining up to 11% on strong Q4 ear...
- Wockhardt shares jump 9% after strong Q4 turnaround, robust FY26 growthWockhardt shares saw a significant jump on Tuesday. The pharmaceutical company reported a strong turnaround in its March quarter performanc...
- Wockhardt to sell 62 products, Baddi unit to Dr Reddy’s for Rs 1,850 croreIn a regulatory filing on Wednesday, Wockharrdt said Dr Reddy’s Labs will acquire 62 products and its unit in Baddi, Himachal Pradesh in a ...
- Wockhardt plans to demerge its formulations biz, dilute stakeAt present, Khorakiwala himself is engaged in negotiations with a clutch of PE funds.
- How Wockhardt Chairman Habil Khorakiwala plans to pull the company out of trouble45 years after he made a profound statement about dying only once, the chairman of Wockhardt would like to repeat it to investors, regulato...
- USFDA directs Wockhardt to hire consultant to check dataUSFDA has warned Wockhardt that lack of accuracy and reliability of data it has reported is a serious violation of good manufacturing pract...
- Why multibagger Wockhardt is on analysts' 'sell' radar nowFundamental troubles or the regulatory problems are not going to go away in a hurry for Wockhardt and it has become more of a trading stock...
- Wockhardt revenues may dip up to $250 m on USFDA banWockhardt may suffer an annual revenue fall of up to $250 million and its American operations may grind to a halt.
- Wockhardt Q1 Net dips 14 per cent to Rs 323 croreNet sales rose to Rs 1,358.37 crore for the first quarter, compared to Rs 1,341.44 crore during the same period of previous fiscal.
- R&D and launch of new generic drugs to boost US business: WockhardtDrug firm Wockhardt has said it will ride on its investments in R&D and launch of new generic drugs for its future growth in the US.
- Wockhardt acquires US-based Morton GrovePharmaceutical major Wockhardt Ltd has acquired Morton Grove Pharmaceuticals, a liquid generic and specialty dermatology company in the US ...
Load More
